ArticleNature communications2025
Macrophage-induced reduction of bacteriophage density limits the efficacy of in vivo pulmonary phage therapy.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Modeling Phage-Antibiotic Synergy, Innate Immunity, and Phage Resistance in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Virobiome-mediated regulation of microbiota-gut-brain axis signaling and neuroimmune homeostasis.Cell communication and signaling : CCS · 2026Review
- Towards modeling phage therapy.PLoS computational biology · 2026Article
- Cross-reactive anti-prophage antibodies and bacterial heteroresistance implicated in phage therapeutic failure.Nature medicine · 2026Article
- AUBFM01 Phage as a Therapeutic Candidate Against MDRMicroorganisms · 2026Article
- Alginate encapsulation enhanced the gastrointestinal stability and bactericidal efficacy of an optimized Salmonella phage cocktail for oral delivery in poultry feed.Poultry science · 2026Article
- Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026Review
- Short-term antagonism between bacteriophages and macrophages decreases with bacteria-phage coevolution.The ISME journal · 2026Article
- When bacteriophages encounter macrophages during their journey through the human body.Frontiers in cellular and infection microbiology · 2026Review
- Harnessing phages in the age of antibiotic resistance: immunological perspectives.Frontiers in immunology · 2026Review
- Phage therapy againstFrontiers in microbiology · 2026Review
- Genomic, Evolutionary and Phenotypic Insights intoViruses · 2025Article
- Article
- Preventive Immunology for Livestock and Zoonotic Infectious Diseases in the One Health Era: From Mechanistic Insights to Innovative Interventions.Veterinary sciences · 2025Review
- Multi-strain phage induced clearance of bacterial infections.PLoS computational biology · 2025Article
- Neutrophils, not macrophages, aid phage-mediated control of pulmonaryFrontiers in immunology · 2025Article
- Analysis of a model for bacteriophage infections and bacteria defense: a synergetics perspective.Frontiers in network physiology · 2025Article
- "French Phage Network" annual conference: ninth meeting report.microLife · 2025Article
- Metapopulation model of phage therapy of an acutemSystems · 2024Article
- Multi-strain phage induced clearance of bacterial infections.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
The rise of antimicrobial resistance leads to renewed interest in evaluating phage therapy. In murine models highly effective treatment of acute pneumonia caused by Pseudomonas aeruginosa relies on the synergistic antibacterial activity of bacteriophages with neutrophils. Here, we show that depletion of alveolar macrophages (AM) shortens the survival of adult male mice without boosting the P. aeruginosa load in the lungs. Unexpectedly, upon bacteriophage treatment, pulmonary levels of P. aeruginosa are significantly lower in AM-depleted than in immunocompetent mice. To explore potential mechanisms underlying the benefit of AM-depletion in treated mice, we develop a mathematical model of bacteriophage, bacteria, and innate immune system dynamics. Simulations from the model fitted to data suggest that AM reduce bacteriophage density in the lungs. We experimentally confirm that the in vivo decay of bacteriophage is faster in immunocompetent compared to AM-depleted animals and that AM phagocytize therapeutic bacteriophage. These findings demonstrate the involvement of feedback between bacteriophage, bacteria, and the immune system in shaping the outcomes of phage therapy in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.